Donald A. Bergstrom - 06 Jul 2022 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Role
President, R&D
Signature
/s/ Brian Adams, as attorney-in-fact
Issuer symbol
RLAY
Transactions as of
06 Jul 2022
Net transactions value
-$127,040
Form type
4
Filing time
08 Jul 2022, 16:17:39 UTC
Previous filing
28 Jun 2022
Next filing
29 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $32,960 +8,000 +8.7% $4.12 99,494 06 Jul 2022 Direct F1, F2
transaction RLAY Common Stock Sale $160,000 -8,000 -8% $20.00 91,494 06 Jul 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -8,000 -4.5% $0.000000 170,456 06 Jul 2022 Common Stock 8,000 $4.12 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 7, 2022.
F2 Includes 84,953 shares underlying restricted stock units.
F3 Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder shall vest in equal quarterly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.